Nicholas Investment Partners LP Acquires 123,891 Shares of Xenon Pharmaceuticals Inc. $XENE

Nicholas Investment Partners LP grew its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 104.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 242,989 shares of the biopharmaceutical company’s stock after purchasing an additional 123,891 shares during the quarter. Nicholas Investment Partners LP’s holdings in Xenon Pharmaceuticals were worth $10,891,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Kestra Advisory Services LLC bought a new stake in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $33,000. Blue Trust Inc. raised its holdings in shares of Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 717 shares in the last quarter. Danske Bank A S bought a new stake in shares of Xenon Pharmaceuticals in the 3rd quarter valued at about $32,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $43,000. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of Xenon Pharmaceuticals in the 3rd quarter valued at about $39,000. Institutional investors own 95.45% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on XENE. Wells Fargo & Company restated an “overweight” rating and issued a $69.00 price target on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Royal Bank Of Canada lifted their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Bank of America reaffirmed a “buy” rating on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $77.20.

Xenon Pharmaceuticals Trading Down 0.2%

NASDAQ:XENE opened at $52.10 on Friday. The company has a market cap of $5.04 billion, a PE ratio of -11.09 and a beta of 0.62. Xenon Pharmaceuticals Inc. has a twelve month low of $30.00 and a twelve month high of $63.95. The company’s 50 day moving average is $55.41 and its two-hundred day moving average is $48.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting the consensus estimate of ($1.17). During the same quarter in the previous year, the company posted ($0.83) EPS. As a group, analysts expect that Xenon Pharmaceuticals Inc. will post -4.92 EPS for the current fiscal year.

Insider Activity at Xenon Pharmaceuticals

In other news, Director Gary Patou sold 1,322 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the sale, the director directly owned 24,896 shares of the company’s stock, valued at $1,322,973.44. This represents a 5.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gillian Cannon sold 1,190 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the sale, the director directly owned 1,455 shares in the company, valued at $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 4.07% of the stock is currently owned by insiders.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.